Summary
BeiGene, Ltd. (ONC) filed an 8-K on June 17, 2021, reporting key outcomes from its 2021 Annual General Meeting of Shareholders and a significant clinical trial update. The shareholders approved amendments to the Company's Articles of Association, including changes related to share transfers, general meeting procedures (allowing for virtual or hybrid meetings), and the establishment of U.S. federal courts as the exclusive forum for Securities Act claims. These amendments are largely in preparation for the proposed listing of RMB Shares on the STAR Market in Shanghai. The meeting also saw the re-election of all Class II directors, ratification of the appointment of independent auditors Ernst & Young, and approval of a general mandate to issue shares. Notably, several proposals related to "Connected Person Placing Authorizations" were approved, allowing for the allocation of shares to existing significant shareholders (Baker Bros. Advisors LP, Hillhouse Capital Management, Ltd., and Amgen Inc.) to maintain their respective shareholding percentages during future offerings, including those related to the STAR Market listing. Additionally, shareholders approved the grant of an option to Amgen to maintain a ~20.6% ownership and the grant of Restricted Stock Units (RSUs) to key executives and directors. In a separate but significant announcement, BeiGene also reported the dosing of the first patient in the global Phase 3 AdvanTIG-302 trial for its investigational anti-TIGIT antibody, ociperlimab, in combination with tislelizumab, for non-small cell lung cancer. This marks a critical step in the pivotal program for ociperlimab, a potential key growth driver for the company.
Key Highlights
- 1Shareholders approved amendments to the Articles of Association, including provisions for virtual/hybrid shareholder meetings and exclusive federal forum for U.S. Securities Act claims, effective upon STAR Market listing.
- 2All Class II directors were re-elected at the Annual General Meeting.
- 3The appointment of Ernst & Young as independent auditors for FY2021 was ratified.
- 4A general mandate was approved, allowing the board to issue up to 20% of outstanding shares.
- 5Shareholder approval was granted for "Connected Person Placing Authorizations" to facilitate share allocation to key investors (Baker Bros., Hillhouse, Amgen) to maintain their ownership percentages in future offerings, including those related to the STAR Market listing.
- 6An option was approved for Amgen to subscribe for shares to maintain approximately 20.6% ownership.
- 7The company announced the dosing of the first patient in a global Phase 3 trial for its anti-TIGIT antibody ociperlimab (BGB-A1217) in combination with tislelizumab for non-small cell lung cancer.